Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04250207 · ClinicalTrials.gov registry record · Phase 2
Study to Investigate the Safety and Efficacy of K-321 in Patients With Fuchs Endothelial Corneal Dystrophy (FECD) Following Descemetorhexis
A Phase 2 study, sponsored by Kowa Research Institute.
- Completed
- Registry status
- Phase 2
- Development phase
- 65
- Enrollment target
NCT04250207 is a Phase 2 study that has completed, run by Kowa Research Institute. The registered enrollment target is 65 participants.
The verdict
NCT04250207, a Phase 2 study, has completed, sponsored by Kowa Research Institute.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 65 participants
- Enrollment target
Study Summary
The objective of this study is to investigate the effect of K-321 in patients with Fuchs endothelial corneal dystrophy (FECD) after descemetorhexis.
Interventions
- DRUG Placebo Solution
- DRUG K-321 Solution
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 65 participants |
| Start Date | 2020-06-23 |
| Est. Completion | 2022-06-27 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04250207
The ClinicalTrials.gov registry entry for NCT04250207 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 65 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Kowa Research Institute, which has 44 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo Solution is the first listed.
NCT04250207 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04250207 about?
NCT04250207 is a clinical study titled "Study to Investigate the Safety and Efficacy of K-321 in Patients With Fuchs Endothelial Corneal Dystrophy (FECD) Following Descemetorhexis". The objective of this study is to investigate the effect of K-321 in patients with Fuchs endothelial corneal dystrophy (FECD) after descemetorhexis.
What is the current status of trial NCT04250207?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 65 participants. The study started on 2020-06-23. Estimated completion is 2022-06-27.
What interventions are being tested in trial NCT04250207?
The interventions under investigation include: Placebo Solution (DRUG), K-321 Solution (DRUG).
Who is sponsoring clinical trial NCT04250207?
This trial is sponsored by Kowa Research Institute, which has 44 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.